{"id":"NCT02059278","sponsor":"Nephron Pharmaceuticals Corporation","briefTitle":"Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","officialTitle":"A Randomized, Multicenter, Parallel-Group, Observer-Masked, Phase 3 Study to Compare the Safety and Efficacy of T-2345 Ophthalmic Solution to Xalatan (Latanoprost 0.005%) in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-01","primaryCompletion":"2015-01","completion":"2015-01","firstPosted":"2014-02-11","resultsPosted":"2018-08-22","lastUpdate":"2018-08-22"},"enrollment":335,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Primary Open Angle Glaucoma","Ocular Hypertension"],"interventions":[{"type":"DRUG","name":"T-2345","otherNames":[]},{"type":"DRUG","name":"Xalatan","otherNames":[]}],"arms":[{"label":"T-2345","type":"EXPERIMENTAL"},{"label":"Xalatan","type":"EXPERIMENTAL"}],"summary":"This is a Phase 3 study to evaluate the safety and efficacy of T-2345 dosed to one of both eyes once daily for 84 days compared to Xalatan dosed to one of both eyes once daily for 84 days in patients with elevated eye pressure.","primaryOutcome":{"measure":"Intraocular Pressure","timeFrame":"Measured at 8am 10 am and 4 pm at Baseline and on Days 15, 42 and 84","effectByArm":[{"arm":"T-2345","deltaMin":-3,"sd":3.2},{"arm":"Xalatan","deltaMin":-3.8,"sd":3.4}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0091"},{"comp":"OG000 vs OG001","p":"0.0098"},{"comp":"OG000 vs OG001","p":"0.0398"},{"comp":"OG000 vs OG001","p":"0.1008"},{"comp":"OG000 vs OG001","p":"0.0558"},{"comp":"OG000 vs OG001","p":"0.0491"},{"comp":"OG000 vs OG001","p":"0.0025"},{"comp":"OG000 vs OG001","p":"0.0113"},{"comp":"OG000 vs OG001","p":"0.0649"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":165},"commonTop":["Instillation site pain","Conjunctival hyperemia","Blepharitis","Punctate keratitis","Vitreous detachment"]}}